EXCELLA™ First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions
EuroInterv.2008;4:53-58.
J. Ribamar Costa Jr1, MD; Alexandre Abizaid1*, MD, PhD; Fausto Feres1, MD, PhD; Ricardo Costa1, MD; Ana Cristina Seixas1, MD; Felipe Maia1, MD; Andrea Abizaid1, MD, PhD; Luis Fernando Tanajura1, MD, PhD; Rodolfo Staico1, MD; Dimytri Siqueira1, MD; Lynn Meredith2, Vinayak Bhat, PhD; John Yan2; John Ormiston3, MD; Amanda G.M.R. Sousa1, MD, PhD; Peter Fitzgerald4, MD, PhD; J. Eduardo Sousa1, MD, PhD
1. Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; 2. Elixir Medical, Sunnyvale, California, USA; 3. Auckland City Hospital, Auckland, New Zealand; 4. Stanford University Medical Center, Stanford, California, USA
Aims: First generation DES have markedly reduced restenosis. However, there is a major interest in developing new DES with greater flexibility, radiopacity and safety profile. The Elixir Me